NCT04407247View on ClinicalTrials.gov

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
ColitisLung Non-Small Cell CarcinomaMalignant Genitourinary System NeoplasmMalignant Solid NeoplasmMelanoma
Interventions
BIOLOGICAL

Infliximab

Given IV

BIOLOGICAL

Vedolizumab

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER